Figure 4From: An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain Patient and investigator global evaluations at month 1 and end point (overall and by previous treatment). Scale: 0 = poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent. CR, controlled-release.Back to article page